DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for chorioretinitis — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleChorioretinitis maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for chorioretinitis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
nuclear receptor subfamily 3 group C member 1 (NR3C1) — NR3C1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7KW7 · 3.57 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
A controlled trial from 1971 randomly assigned 29 patients with presumed histoplasmic choroiditis to light coagulation or no treatment. After one year, the therapy showed no value in long-term management of the disease.
A 2017 double-blind randomised trial compared quadruple therapy (cotrimoxazole, clindamycin, and oral corticosteroid) against triple therapy (pyrimethamine, sulphadiazine, and oral corticosteroid) in toxoplasmic chorioretinitis. The quadruple group had a higher percentage of lesion remission at the first follow-up visit (p=0.001). Over the entire study, the mean percentage remission was 57.5% (median 70.9%) in the quadruple group versus 52.5% (median 54.0%) in the triple group, a difference that was not statistically significant (p=0.720). The quadruple regimen produced faster initial resolution but no clear advantage in overall remission.
A 2016 mouse study of herpetic chorioretinitis fed animals diets rich in n-3 polyunsaturated fatty acids (Menhaden oil), n-6 PUFAs (safflower oil), or saturated fats (corn oil). Mice on the n-3 diet developed contralateral chorioretinitis earlier (by day 6 after inoculation) and had significantly higher HSV-1 RNA expression than the other groups. They also showed decreased secretion of TNF-α, IFN-γ, IL-2, and IL-10 in splenic cells and retinas. The n-3 PUFAs appeared to worsen the infection in this model.
What remains missing is any large, modern, randomised trial for histoplasmic chorioretinitis, a clear stratification of patients by aetiology (toxoplasma, herpes, histoplasma) in future drug studies, and funding to move the quadruple therapy finding beyond a single modest trial with a non-significant overall endpoint.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Ophthalmology · 1971 · 15 citations
Light Coagulation in Presumed Histoplasmic Choroiditis
AbstractA controlled study was designed to evaluate light coagulation as treatment for presumed histoplasmic chorioretinitis. Twenty-nine patients were selected. Allocation of patients to a treatment or an untreated control group was made by using a table of random numbers. Results in the two groups were compared over a one-year observation period. The study was designed to minimize measurement and observation bias and the effect of interim remissions and exacerbations of the disease. The results indicate that this therapy is of no value in the long-term management of this disease.
Clinical ophthalmology · 2017 · 10 citations · open access
Rapid resolution of toxoplasma chorioretinitis treatment using quadruple therapy
AbstractPurpose: To compare the effectiveness of quadruple-drug therapy consisting of cotrimoxazole (trimethopin and sulfamethoxazole), clindamycin antibiotics, and oral corticosteroid versus triple therapy consisting of pyrimetamine, sulphadiazine, and oral corticosteroid in the resolution of toxoplasmic chorioretinitis. Methods: This was a double-blind randomized controlled trial with repeated measures using parallel design to compare the effectiveness of quadruple-drug therapy and triple-drug therapy in patients with toxoplasmic chorioretinitis. The measurement of lesion was done using automated computer software, calculating the average of lesion size from three fundus photographs taken from the baseline and at each follow-up visit. The analytical statistics were obtained using Mann–Whitney test, comparing percentage of lesion remission test in each examination. Results: The percentage of lesion remission in quadruple-drug therapy was higher than in triple-drug therapy from the first visit until the first follow-up visit, with a p -value of 0.001. In addition, the mean percentage of lesion remission from first visit to last visit was 57.5% and the median was 70.9% in the quadruple therapy group, while in the triple-drug therapy group the mean was 52.5% and the median was 54.0% ( p =0.720). Conclusion: We conclude that the quadruple-drug therapy has a more rapid resolution effect on chorioretinitis lesion compared to triple therapy. Keywords: toxoplasma chorioretinitis, quadruple-drug therapy, triple-drug therapy
Ocular Immunology and Inflammation · 2016 · 7 citations
Effects of PUFAs in a Mouse Model of HSV-1 Chorioretinitis
AbstractPURPOSE: To examine the effects of n-3 and n-6 polyunsaturated fatty acids (n-3 and n-6 PUFAs) in a murine model of herpetic chorioretinitis. METHODS: BALB/c mice were fed on three high fat diets, which contained: Menhaden oil (rich in n-3 PUFAs); Safflower oil (rich in n-6 PUFAs); or Corn oil (rich in saturated fatty acids) as control group, 14 days previously and until 12 days following anterior chamber (AC) HSV-1 inoculation. RESULTS: Mice fed on Menhaden oil present an early development of contralateral chorioretinitis by day 6 post-AC HSV-1 inoculation and also significant increase of RNA HSV-1 expression compared with Safflower and Corn oil groups. Furthermore, mice fed on Menhaden oil showed a significant decrease secretion of TNF-α, IFN-γ, IL-2 and IL-10 in splenic cells and both retinas. CONCLUSION: Our results showed that mice fed on Menhaden oil (n-3 PUFAs) presented an early development of contralateral chorioretinitis by day 6 post-AC HSV-1 inoculation and also a significant increase in RNA HSV-1 expression compared with animals fed on Safflower and Corn oils. This increase of HSV-1 could be associated with the higher development of chorioretinitis.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
